Press release - 04/11/2026 Molecular guardian inhibits aggressive brain tumor's ability to switch between identities One of the reasons for the high aggressiveness of glioblastomas is their remarkable adaptability. A team led by scientists from the German Cancer Research Center (DKFZ), the EMBL, HITBR*, and the Wellcome Sanger Institute, Cambridge, now describes how glioblastoma cells switch between different states. At the same time, they identified a key factor that, acting as a guardian of cell identity, limits this adaptability.https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-guardian-inhibits-aggressive-brain-tumors-ability-switch-between-identities
Press release - 02/11/2026 Stem Cells in Deep Sleep as a Secret Reserve Researchers at the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute have discovered a group of particularly long-lived blood stem cells in mice. These cells remain in a dormant state for an exceptionally long time while retaining their ability to generate new blood cells. This newly discovered cell population may be responsible for sustaining blood regeneration and immune defense throughout a mouse’s entire life.https://www.gesundheitsindustrie-bw.de/en/article/press-release/stem-cells-deep-sleep-secret-reserve
Press release - 02/11/2026 Heidelberger researchers receive Else Kröner memorial fellowships for projects on kidney disease and AI-based diagnostics Why do certain congenital kidney disorders vary so widely in severity among affected individuals? Can AI improve breast cancer diagnostics? These are the questions being addressed in current projects by two early-career researchers at the Heidelberg Faculty of Medicine at Heidelberg University. https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberger-researchers-receive-else-kroner-memorial-fellowships-projects-kidney-disease-and-ai-based-diagnostics
Press release - 29/10/2026 New Approach Could Make Immunotherapy for Blood Cancer More Precise Researchers at the Faculty of Medicine – University of Freiburg have developed a new approach to specifically target an aggressive form of blood cancer while better sparing healthy immune cells. In what is known as T-cell acute lymphoblastic leukemia (T-ALL), cancer cells develop from the body’s own immune defense cells. This complicates treatment, as immunotherapies studied to date can also destroy healthy immune cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-could-make-immunotherapy-blood-cancer-more-precise
Press release - 28/10/2026 A Discovery in Freiburg Makes Cancer Immunotherapy Better Tolerated A discovery made in Freiburg opens up new treatment options for cancer patients worldwide: Researchers at the Medical Center – University of Freiburg have discovered how severe side effects of cancer immunotherapies can be alleviated using a specialized cell therapy involving treated white blood cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/discovery-freiburg-makes-cancer-immunotherapy-better-tolerated
Press release - 26/10/2026 Multiple sclerosis: New treatment significantly reduces relapses A new treatment could improve care for people with relapsing multiple sclerosis (MS). In two international studies involving a total of 2,007 patients, remibrutinib reduced the annualized relapse rate by 31% to 35% compared with an established MS therapy. New inflammatory brain lesions were also significantly less frequent. In addition, there are indications that the treatment may slow the progression of physical disability.https://www.gesundheitsindustrie-bw.de/en/article/press-release/multiple-sclerosis-new-treatment-significantly-reduces-relapses
Press release - 20/10/2026 How randomness makes artificial vision more reliable Humans are usually remarkably good at recognising objects, even under poor viewing conditions. Artificial vision systems, by contrast, reach their limits more quickly when images are distorted or unfamiliar. Researchers at the Hertie Institute for Clinical Brain Research (HIH) have now investigated what artificial vision systems can learn from the brain.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-randomness-makes-artificial-vision-more-reliable
Press release - 19/10/2026 New Biotech Master’s Degree Launches at Ulm University: Pharmaceutical and Molecular Biotechnology How do RNA-, protein- or stem cell-based therapies work? How can data science methods from bioinformatics and artificial intelligence be used to develop new pharmaceutical active substances? Students at Ulm University are learning this in the new master’s programme in Pharmaceutical and Molecular Biotechnology (PMB).https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-biotech-masters-degree-launches-ulm-university-pharmaceutical-and-molecular-biotechnology
Press release - 16/10/2026 A new approach to osteoporosis treatment Disabling a bone formation inhibiting protein molecule How can the human body be stimulated to build more bone, thus helping those affected by osteoporosis? Researchers in Ulm have investigated the role played by the protein molecule Axl in this process. Their efforts were successful: in a study, they demonstrated that Axl inhibits bone formation – and that cells produce significantly more bone tissue when the molecule is blocked using medication. There are no discernible harmful side effects. https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-osteoporosis-treatment-disabling-bone-formation-inhibiting-protein-molecule
Press release - 16/10/2026 Epilepsy: AI Aims to Improve Treatment with Brain Pacemakers About 250,000 people in Germany live with epilepsy that does not respond adequately to medication. How can their treatment be further improved with a brain pacemaker? As part of the CLOUDIA research project, the Medical Center – University of Freiburg is now collaborating with a medical technology company to develop an AI-supported assistance system for analyzing long-term brain activity data.https://www.gesundheitsindustrie-bw.de/en/article/press-release/epilepsy-ai-aims-improve-treatment-brain-pacemakers
Press release - 08/10/2026 High iron levels may promote the mobility of brain tumor cells Iron is essential for healthy cells. Cancer cells also require this trace element. Researchers in Freiburg have now found evidence that high levels of iron directly in the tumor microenvironment promote the spread of certain cells in a particularly aggressive type of brain tumor known as glioblastoma. In the long term, iron metabolism could therefore serve as a target for more precisely influencing particularly invasive tumor cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/high-iron-levels-may-promote-mobility-brain-tumor-cells
Press release - 06/10/2026 Harnessing Synthetic Cellular Systems as Immune Cell Boosters How can cell-based immunotherapies for cancer and autoimmune diseases become more widely available in the long term? The SYNTHIA project is addressing this challenge: The Max Planck Institute for Medical Research and the Fraunhofer Institute for Cell Therapy and Immunology IZI are collaborating on new research approaches to advance the development of cell-based immunotherapies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/harnessing-synthetic-cellular-systems-immune-cell-boosters
Press release - 05/10/2026 How blood flow controls liver function The liver is organized into distinct zones in which liver cells perform different functions. The blood vessels of the liver play an important role in this spatial organization: the endothelial cells lining the vessels provide signals that instruct neighboring liver cells and help determine their function. But how do endothelial cells know which signals to produce?https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-blood-flow-controls-liver-function
Press release - 01/10/2026 New AI Agent to Capture and Analyze Patient Experiences for Healthcare Delivery and Health Systems An international consortium led by researchers at the Heidelberg Faculty of Medicine at Heidelberg University will develop an AI-powered interactive assistant for the analysis of patient experiences over the next four years. The goal is to identify individual burdens and challenges early and comprehensively and make this information actionable for patients, care teams, and health systems.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-ai-agent-capture-and-analyze-patient-experiences-healthcare-delivery-and-health-systems
Press release - 30/09/2026 How cells pass on regulatory information A project funded by the Baden-Württemberg Stiftung at the Max Planck Institute of Immunobiology and Epigenetics in Freiburg is investigating the interplay between RNA modifications and epigenetic mechanisms during cell division – and its potential significance for treatment resistance in cancer.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-cells-pass-regulatory-information
Press release - 23/09/2026 ViferaXS Raises €12 Million to Advance Phase II Trial in Chronic Lymphocytic Leukemia and Expand Its Oncology Pipeline ViferaXS, a clinical-stage biotechnology company developing peptide-based cancer immunotherapy for hematologic malignancies and solid tumors, today announced the close of the Series A financing round of up to €12 million, including grant funding. The round was led by SPRIND, the German Federal Agency for Breakthrough Innovation, and Huma, with participation from private investors.https://www.gesundheitsindustrie-bw.de/en/article/press-release/viferaxs-raises-euro-12-million-advance-phase-ii-trial-chronic-lymphocytic-leukemia-and-expand-its-oncology-pipeline
Press release - 16/09/2026 Professor Jakob Nikolas Kather Appointed Hopp Foundation Professor of “Artificial Intelligence in Medicine” and Founding Director of the New Institute for Medical AI (IMAI) in Heidelberg Effective 1 October 2026, Professor Jakob Nikolas Kather will assume the Hopp Foundation Professorship for “Artificial Intelligence in Medicine” at the Heidelberg Faculty of Medicine at Heidelberg University. Associated with the professorship is the establishment of the new Institute for Medical AI (IMAI) at Heidelberg University Hospital, which Professor Kather will lead as its founding director.https://www.gesundheitsindustrie-bw.de/en/article/press-release/professor-jakob-nikolas-kather-appointed-hopp-foundation-professor-artificial-intelligence-medicine-and-founding-director-new-in
Press release - 09/09/2026 International Research on Bioengineering of the Mitochondrial Genome While the cell nucleus contains almost all of the genome, the mitochondria – the powerhouses of the cell – have their own small genetic code. It consists of only 37 genes, which are organized in circular DNA – mtDNA, for short. Defects in the mitochondrial genome are related to incurable neurodegenerative and metabolic diseases, cancer and also aging processes.https://www.gesundheitsindustrie-bw.de/en/article/press-release/international-research-bioengineering-mitochondrial-genome
Press release - 08/09/2026 Quality Over Quantity: New Insights into the Role of Specific CAR T Cells in Cancer Therapy CAR T-cell therapies are used successfully to treat certain blood cancers. However, while some patients respond even to low-dose treatment, others derive no benefit. Researchers from the Heidelberg Faculty of Medicine at Heidelberg University and the Berlin Institute of Health at Charité (BIH) investigated the reasons behind these differences in a collaborative research project.https://www.gesundheitsindustrie-bw.de/en/article/press-release/quality-over-quantity-new-insights-role-specific-car-t-cells-cancer-therapy
Press release - 03/09/2026 ERC Starting Grant for Heidelberg Neurologist and Neuroscientist Dr. Dr. Varun Venkataramani Cells of the highly aggressive brain tumor glioblastoma exhibit predatory behavior: they exploit signaling between healthy neurons and internalize portions of their contact sites. Dr. Dr. Varun Venkataramani of the Heidelberg Medical Faculty of Heidelberg University, and his research team, will investigate how glioblastoma cells benefit from this process and whether it may represent a novel therapeutic target.https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-starting-grant-heidelberg-neurologist-and-neuroscientist-dr-dr-varun-venkataramani
Funding FIGHT KIDS CANCER 2026-2027 Competitive Call Funding programme, Funded by: Fight Kids Cancer, sb_search.searchresult.label.programSubmissionDate: 13/10/2026 https://www.gesundheitsindustrie-bw.de/en/database/funding/fight-kids-cancer-2026-2027-competitive-call
Press release - 01/09/2026 Early Detection of COPD: A Study in Freiburg Investigates a New Treatment Coughing, phlegm, and shortness of breath can be early signs of COPC. In COPD, the airways are permanently narrowed, making it harder to breathe. The most significant risk factor is long-term smoking. The CHRONOS study conducted by the Department of Pneumology at the Medical Center – University of Freiburg provides evidence that changes in the lungs can already be detected before a standard pulmonary function test confirms the airway narrowing.https://www.gesundheitsindustrie-bw.de/en/article/press-release/early-detection-copd-study-freiburg-investigates-new-treatment
Press release - 28/08/2026 Outstanding success for Ulm’s quantum physics QuantERA funds four teams Research into quantum technology by four teams at Ulm University is being funded as part of the European QuantERA programme. This is more than at any other German university. The projects focus, for example, on more robust quantum computers and innovative medical diagnostic methods.https://www.gesundheitsindustrie-bw.de/en/article/press-release/outstanding-success-ulms-quantum-physics-quantera-funds-four-teams
Funding Recoding Medicine Competition, Funded by: SPRIN-D, sb_search.searchresult.label.programSubmissionDate: 16/10/2026 https://www.gesundheitsindustrie-bw.de/en/database/funding/recoding-medicine-en
Press release - 13/08/2026 PRAME-specific T-cell therapy in an adolescent with metastatic kidney tumor Researchers and physicians at the Hopp Children's Cancer Center Heidelberg (KiTZ) and other leading cancer centers report an exceptional treatment success in an adolescent with an advanced, therapy-resistant kidney tumor. Using a novel, personalized T-cell therapy, they succeeded in completely pushing back the tumor disease despite multiple metastases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/prame-specific-t-cell-therapy-adolescent-metastatic-kidney-tumor
Press release - 12/08/2026 Industrial-scale biotech production of proteins and vitamins economically viable Researchers are developing biotechnological processes that enable microbes to produce proteins and vitamins for human consumption using basic chemical ingredients, such as carbon dioxide, hydrogen and oxygen – entirely bypassing livestock farming and agriculture. Because these methods also require energy input, they are popularly called “power-to-protein” and “power-to-vitamin” processes.https://www.gesundheitsindustrie-bw.de/en/article/press-release/industrial-scale-biotech-production-proteins-and-vitamins-economically-viable
Press release - 10/08/2026 Immune Cells in Bone Marrow Cancer: Limited Defense Readiness A team led by researchers from the German Cancer Research Center, the HI-STEM* Stem Cell Institute, and Medical Clinic V at Heidelberg University Hospital has characterized T cells in the bone marrow in cases of multiple myeloma and acute myeloid leukemia: A specific group of tumor-reactive T cells can recognize and fight cancer cells, but is often not sufficiently activated. Nevertheless, the number of these cells influences the prognosis.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immune-cells-bone-marrow-cancer-limited-defense-readiness
Press release - 07/08/2026 Can Protein Building Blocks Protect Against Vascular and Kidney Damage? Researchers from the Medical Faculty Heidelberg, the Medical Faculty Mannheim, and the Centre for Organismal Studies at Heidelberg University have launched a new research project investigating so-called dipeptides. The consortium aims to determine which dipeptides have the strongest protective effects and how they could be harnessed in future therapies for vascular and kidney diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/can-protein-building-blocks-protect-against-vascular-and-kidney-damage
Press release - 31/07/2026 A new genetic tool helps researchers uncover the logic of gene regulation Researchers use synthetic biology approaches to test hundreds of DNA sequences for their effect on regulating gene expression. The human genome contains over 20,000 genes. However, at any given time and in a given cell, only a fraction of them are active. Researchers from EMBL Heidelberg’s Krebs Group have come up with an innovative experimental approach to understand how cells determine which genes to turn on and when.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-genetic-tool-helps-researchers-uncover-logic-gene-regulation
Press release - 31/07/2026 New insights into Malaria research: How molecular tethers and Asynchronous replication drive parasite proliferation Researchers from Heidelberg University’s Faculty of Medicine, Harvard Medical School, and the German Cancer Research Center (DKFZ) have uncovered key mechanisms underlying the proliferation of the malaria parasite Plasmodium. The molecular processes that govern the formation of infectious daughter parasites and new nuclei are essential for parasite survival and may therefore represent targets for future antimalarial therapies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-insights-malaria-research-how-molecular-tethers-and-asynchronous-replication-drive-parasite-proliferation
Press release - 24/07/2026 Changes in brain state influence the readiness to form memories Most everyday moments are quickly forgotten, while others stay with us for a lifetime. How the brain determines which memories are retained and which are lost remains an open question. A neuroscience team at the University of Tübingen, has found that spontaneous fluctuations in the brain’s internal state influence how ready the memory system is to store new information. https://www.gesundheitsindustrie-bw.de/en/article/press-release/changes-brain-state-influence-readiness-form-memories
Press release - 23/07/2026 Flabby and flexible: How Machine Learning helps to build new proteins A team of researchers from the Heidelberg Institute for Theoretical Studies and the Max Planck Institute for Polymer Research have developed a model that learns how to generate proteins whose structures are highly flexible, even with patterns that are uncommon in natural proteins. Their work, marks a step towards the goal of designing new proteins for applications in biotechnology, therapeutics and environmental research.https://www.gesundheitsindustrie-bw.de/en/article/press-release/flabby-and-flexible-how-machine-learning-helps-build-new-proteins
Press release - 22/07/2026 The Individual Genetic Background Shapes the Evolution of Cancer Why do cancers develop differently in different people—even when they are exposed to the same risk factors? An international research group, including the German Cancer Research Center (DKFZ), has now demonstrated in mice that an organism’s genetic makeup significantly influences the course of cancer development. https://www.gesundheitsindustrie-bw.de/en/article/press-release/individual-genetic-background-shapes-evolution-cancer
Press release - 20/07/2026 Blood vessels guide immune cells to metastases It has long been suspected that endothelial cells play a key role in determining how the body’s immune system responds to tumors. Researchers at the DKFZ and the Medical Faculty Mannheim of Heidelberg University have now identified, in mouse studies, a specialized population of blood vessel lining endothelial cells that enable an effective immune defense against cancer metastases in the liver. https://www.gesundheitsindustrie-bw.de/en/article/press-release/blood-vessels-guide-immune-cells-metastases
Press release - 17/07/2026 NovoTags: AI-designed proteins help scientists see inside living cells Researchers have designed synthetic and inducible proteins that bind to bright fluorescent dyes with high specificity and affinity, significantly expanding the toolkit for multicolour imaging of proteins inside cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/novotags-ai-designed-proteins-help-scientists-see-inside-living-cells
Press release - 16/07/2026 New Findings on Acute Leukemias: Specific Mutations Provide Targets for More Targeted Therapies Researchers at the NCT Heidelberg and the German Cancer Research Center (DKFZ) have, for the first time, systematically determined how specific mutations promote acute myeloid leukemias. The results show why IDH1- and IDH2-mutated leukemias develop differently despite similar molecular mechanisms—and open up new approaches for diagnostics and targeted therapies. https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-findings-acute-leukemias-specific-mutations-provide-targets-more-targeted-therapies
Press release - 16/07/2026 Impact of Overweight on Cancer Risk May Be Significantly Underestimated Being overweight and obesity may contribute to significantly more cancer cases than previously thought. This is the conclusion reached by researchers at the German Cancer Research Center (DKFZ). Their analysis shows that when more accurate measures of body fat and methodological biases are considered, more than 10 percent of all cancer cases can be attributed to increased body weight - nearly twice as many as previous estimates suggested.https://www.gesundheitsindustrie-bw.de/en/article/press-release/impact-overweight-cancer-risk-may-be-significantly-underestimated
Press release - 14/07/2026 Steering the Formulation of Engineered Tissue by Sound Waves With the aid of physical forces it is possible to actively steer the formation of engineered tissue. For example, sound waves can be used to create functional vascular networks with blood vessel-like structures in vitro. Scientists at the Center for Molecular Biology of Heidelberg University have demonstrated this through their methodology for acoustic manipulation. https://www.gesundheitsindustrie-bw.de/en/article/press-release/steering-formulation-engineered-tissue-sound-waves
Press release - 10/07/2026 University of Hohenheim awarded European University status The University of Hohenheim becomes a European University through the EuroLeague of Life Sciences Universities. For ELLS, which is celebrating its 25th anniversary this year, this marks the beginning of a new chapter. The decision will provide students, researchers and staff at the University of Hohenheim in Stuttgart with increased opportunities to study, work and collaborate with partner universities across Europe.https://www.gesundheitsindustrie-bw.de/en/article/press-release/university-hohenheim-awarded-european-university-status
Press release - 07/07/2026 Polyomaviruses: new approaches to prevention and treatment In people with severely compromised immune systems, the JC polyomavirus can trigger a currently untreatable, usually fatal brain disease. Now, an international research team looking at the viral capsid has identified binding sites for neutralizing antibodies; these sites could be used to halt infection with JC polyomaviruses.https://www.gesundheitsindustrie-bw.de/en/article/press-release/polyomaviruses-new-approaches-prevention-and-treatment
Press release - 06/07/2026 New AI System Provides Treatment Recommendations for Complex Blood Cancers Researchers from the German Cancer Research Center (DKFZ), the HI-STEM* Stem Cell Institute, and the Heidelberg University Hospital (UKHD) have developed “HemaGuide,” an AI assistant that supports physicians in making difficult treatment decisions. In extensive testing, the system has shown a high degree of agreement with the recommendations of experienced experts and could significantly improve access to specialized and personalized cancer care.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-ai-system-provides-treatment-recommendations-complex-blood-cancers
Press release - 03/07/2026 Vaccine Against Brain Tumors Shows Promising Long-Term Results A novel vaccination strategy against certain malignant brain tumors could fundamentally improve treatment for patients. Researchers from the German Cancer Research Center, Mannheim University Medical Center, Heidelberg University Hospital, and numerous partner institutions* have published encouraging long-term results from a clinical trial involving a vaccine that activates the immune system against a common genetic mutation in these tumors.https://www.gesundheitsindustrie-bw.de/en/article/press-release/vaccine-against-brain-tumors-shows-promising-long-term-results
Press release - 02/07/2026 How Tumors Evade Immunotherapy - and How to Prevent It Researchers at the German Cancer Research Center (DKFZ) have identified a previously unknown key mechanism by which cancer cells suppress the immune system and thus evade the effects of immunotherapies. At the same time, the new study in mouse models and human tumor samples points to a promising way to prevent resistance to immunotherapy.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-tumors-evade-immunotherapy-and-how-prevent-it
Press release - 02/07/2026 Virus influences rare brain lymphomas Primary CNS lymphomas in immunocompromised patients are among the rarest and at the same time most aggressive cancers – yet evidence-based recommendations for their diagnosis and treatment have been lacking. An international research team led by the Heidelberg Faculty of Medicine at Heidelberg University and the German Cancer Research Center has now identified characteristic imaging features of these tumors and developed a prognostic model.https://www.gesundheitsindustrie-bw.de/en/article/press-release/virus-influences-rare-brain-lymphomas
Press release - 02/07/2026 Microbial heritage against stress Study points to cross-generational protection provided by an environmental bacterium An environmental bacterium could protect against the effects of stress right through to the next generation. Evidence of this emerged in a study using a mouse model carried out by researchers from Ulm and Frankfurt, the results of which were published in the journal `Molecular Psychiatry´. According to the study, the offspring of treated mothers were better protected against the effects of stress in adulthood than control animals.https://www.gesundheitsindustrie-bw.de/en/article/press-release/microbial-heritage-against-stress-study-points-cross-generational-protection-provided-environmental-bacterium
Press release - 01/07/2026 Double ERC Success for DKFZ Researchers Through its “Proof of Concept” (PoC) grants, the European Research Council (ERC) supports scientists in further developing the economic potential of their research findings. In 2026, two scientists from the German Cancer Research Center (DKFZ) were once again selected to receive this prestigious funding: Moritz Mall and Chong Sun.https://www.gesundheitsindustrie-bw.de/en/article/press-release/double-erc-success-dkfz-researchers
Press release - 01/07/2026 Newly Discovered Marker for Metastatic Colorectal Cancer Is the Achilles’ Heel of Highly Aggressive Tumor Cells A team led by researchers from the German Cancer Research Center and the HI-STEM* Stem Cell Institute has discovered a new approach to treating advanced colorectal cancer. The study identifies a key marker of particularly aggressive and treatment-resistant colorectal cancer cells. At the same time, the researchers demonstrate using models that already approved drugs targeting this marker can specifically attack the metastasis-initiating cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/newly-discovered-marker-metastatic-colorectal-cancer-achilles-heel-highly-aggressive-tumor-cells
Press release - 30/06/2026 Franziska Kolb Prize for personalised leukaemia research Dr. Alexandra Niedermayer receives 8,000 euros Cancer researcher Dr Alexandra Niedermayer from the Ulm Children’s and Adolescents’ Clinic has been awarded the Franziska Kolb Prize, worth 8,000 euros, by the Ulm University Foundation. The 32-year-old researches aggressive forms of blood cancer and, using modern techniques, has identified an effective, personalised treatment approach. https://www.gesundheitsindustrie-bw.de/en/article/press-release/franziska-kolb-prize-personalised-leukaemia-research-dr-alexandra-niedermayer-receives-8000-euros
Press release - 29/06/2026 PFAS in medicines can often be replaced with alternatives Certain medicines contain compounds known as PFAS, which are causing increasing environmental harm due to their long-lasting effects. A report by the University of Freiburg, commissioned by the German Environment Agency, shows that many PFAS-based active ingredients used in medicines can be replaced by alternatives. Based on the findings of the report, doctors will in future be able to give preference to prescribing PFAS-free medicines.https://www.gesundheitsindustrie-bw.de/en/article/press-release/pfas-medicines-can-often-be-replaced-alternatives
Press release - 29/06/2026 Dr. Felix Kommoss awarded the 2026 Rudolf Virchow Prize For his research on the development of rare malignant tumors in the hereditary DICER1 tumor predisposition syndrome, Dr. Felix Kommoss has been awarded the Rudolf Virchow Prize of the German Society of Pathology. Dr. Kommoss conducts research at the Heidelberg Faculty of Medicine at Heidelberg University and serves as Senior Physician and Head of Gynecologic Pathology at the Institute of Pathology, Heidelberg University Hospital.https://www.gesundheitsindustrie-bw.de/en/article/press-release/dr-felix-kommoss-awarded-2026-rudolf-virchow-prize
Press release - 26/06/2026 CRIION Joachim Frank Prize 2026 awarded to cancer researchers in Freiburg On Thursday, 25 June 2026, several Freiburg cancer researchers were honoured at the presentation of the CRIION Joachim Frank Prize 2026. Among them was Prof. Dr Robert Zeiser, who received the Prize for Biomedical Research. Prof. Dr Jürgen Finke, PD Dr Florian Scherer and PD Dr Elisabeth Schorb of the University Medical Center Freiburg, together with Prof. Dr Gerald Illerhaus of Stuttgart Hospital, were awarded the Prize for Clinical Medicine.https://www.gesundheitsindustrie-bw.de/en/article/press-release/criion-joachim-frank-prize-2026-awarded-cancer-researchers-freiburg
Press release - 26/06/2026 CRIION Joachim Frank Prize 2026 awarded to cancer researchers in Freiburg On Thursday, 25 June 2026, several Freiburg cancer researchers were honoured at the presentation of the CRIION Joachim Frank Prize 2026. Among them was Prof. Dr Robert Zeiser, who received the Prize for Biomedical Research. Prof. Dr Jürgen Finke, PD Dr Florian Scherer and PD Dr Elisabeth Schorb of the University Medical Center Freiburg, together with Prof. Dr Gerald Illerhaus of Stuttgart Hospital, were awarded the Prize for Clinical Medicine.https://www.gesundheitsindustrie-bw.de/en/article/press-release/criion-joachim-frank-prize-2026-awarded-cancer-researchers-freiburg-1
Press release - 25/06/2026 Surroundings influence developing biology of the eye In a virtual reality study involving zebrafish, researchers from the University of Konstanz and King’s College London have discovered that the development of the eye is influenced by what the fish see during the early stages of life – and this, in turn, alters their behaviour.https://www.gesundheitsindustrie-bw.de/en/article/press-release/surroundings-influence-developing-biology-eye
Press release - 25/06/2026 Four Doctoral Candidates from Heidelberg University at the Lindau Nobel Laureate Meeting Four doctoral candidates from Heidelberg University have the opportunity to exchange ideas with outstanding scientists. They are set to take part in the 75th Lindau Nobel Laureate Meeting, which is being held in Lindau from 28 June to 3 July 2026. Jana Braunger, Tim Schubert, Laura Rueda Gensini and Nathan Trausch are among around 600 young researchers who have been selected for their outstanding academic achievements. https://www.gesundheitsindustrie-bw.de/en/article/press-release/four-doctoral-candidates-heidelberg-university-lindau-nobel-laureate-meeting
Press release - 19/06/2026 Universität Heidelberg: Humboldt professorship for leading international researcher In order to further strengthen Heidelberg University as an internationally recognized location of infection research, Prof. Dr Mathias Lichterfeld has been selected for an Alexander von Humboldt Professorship endowed with 7.8 million euros. Leading international academics are granted this most valuable of German research awards to enable them to conduct long-term, cutting-edge research at German universities.https://www.gesundheitsindustrie-bw.de/en/article/press-release/universitaet-heidelberg-humboldt-professorship-leading-international-researcher
Press release - 18/06/2026 Tailor-made functionalized gelatin – manufactured with reproducible results Gelatin is a versatile natural material. To tailor its properties specifically to the various applications in medicine, diagnostics, and cosmetics, the Fraunhofer IGB has developed a toolbox for chemical functionalization. With the help of automated processes, the modifications can now be scaled under defined conditions, and reproducible batches of modified gelatin can be produced on a scale ranging from grams to kg for customer sampling.https://www.gesundheitsindustrie-bw.de/en/article/press-release/tailor-made-functionalized-gelatin-manufactured-reproducible-results
Press release - 12/06/2026 The University of Freiburg and Nagoya University agree on a joint doctoral programme The University of Freiburg and Nagoya University are strengthening their strategic partnership through a joint doctoral programme and the Nagoya University Global Campus, which serves as a permanently staffed representative office in Freiburg.https://www.gesundheitsindustrie-bw.de/en/article/press-release/university-freiburg-and-nagoya-university-agree-joint-doctoral-programme
Press release - 10/06/2026 Can Aztekin receives 2026 Schering Young Investigator Award This year’s Schering Young Investigator Award has been awarded to Can Aztekin, a Max-Planck-Research Group Leader at the Friedrich Miescher Laboratory of the Max Planck Society in Tübingen, to recognize his significant work in the field of regenerative biology.https://www.gesundheitsindustrie-bw.de/en/article/press-release/can-aztekin-receives-2026-schering-young-investigator-award
Press release - 10/06/2026 AI Diagnoses Brain Tumors in Minutes Instead of Weeks Experts in Heidelberg have developed an AI system that can classify brain tumors with unprecedented accuracy using standard microscopic tissue sections. Using digitized standard stains, the system identifies more than 100 molecular subtypes of central nervous system tumors, delivers results within minutes, and could accelerate the diagnosis of brain tumors worldwide.https://www.gesundheitsindustrie-bw.de/en/article/press-release/ai-diagnoses-brain-tumors-minutes-instead-weeks
Press release - 03/06/2026 Potential Biomarker for personalized Leukemia therapy identified Researchers at Heidelberg Faculty of Medicine at Heidelberg University, in collaboration with partners from 29 German study centers, have found evidence of a potential biomarker for personalized therapy of acute myeloid leukemia (AML) in a Phase II study. Analyses showed that certain patients could benefit from additional treatment with the drug Motixafortide in addition to standard chemotherapy.https://www.gesundheitsindustrie-bw.de/en/article/press-release/potential-biomarker-personalized-leukemia-therapy-identified
Press release - 03/06/2026 Fat hack protects against cell death In response to stress or damage, cells undergo senescence and stop dividing. However, if senescent cells accumulate in tissues over the long term, chronic inflammation occurs and the risk of cancer increases. Researchers at the German Cancer Research Center (DKFZ) have now discovered a previously unknown mechanism by which senescent cells protect themselves from oxidative stress and a specific form of cell death known as ferroptosis. https://www.gesundheitsindustrie-bw.de/en/article/press-release/fat-hack-protects-against-cell-death
Press release - 02/06/2026 New approach to prevent treatment-induced leukemia Protective mechanism against DNA damage caused by chemotherapy and radiotherapy discovered In rare cases, cancer treatments can cause serious long-term effects. These include so-called secondary leukemias. This form of blood cancer can develop when chemotherapy or radiotherapy damages the genetic material of healthy cells. A research team led by a scientist from Ulm has now discovered a molecular protective mechanism against such genomic damage: a peptide.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-prevent-treatment-induced-leukemia-protective-mechanism-against-dna-damage-caused-chemotherapy-and-radiotherapy-dis
Press release - 01/06/2026 Central Institute of Mental Health joins international Lancet Commission on schizophrenia Leading scientists are pooling their expertise to further advance research and care for psychotic disorders and to align them more closely with the needs of affected individuals. https://www.gesundheitsindustrie-bw.de/en/article/press-release/central-institute-mental-health-joins-international-lancet-commission-schizophrenia
Press release - 01/06/2026 More precise therapeutic agents for neuropsychiatry: The NMI is helping to unravel complex receptor mechanisms How can effective treatments for neuropsychiatric disorders be developed without having to accept unwanted side effects? Researchers at the NMI have made an important contribution to this field. In their recent paper, “NMDA receptor subtype differential affinity as a key enabler for precision neuropsychiatry,” they demonstrate how specifically targeting subunits of the NMDA receptor opens up new avenues for safer medications.https://www.gesundheitsindustrie-bw.de/en/article/press-release/more-precise-therapeutic-agents-neuropsychiatry-nmi-helping-unravel-complex-receptor-mechanisms
Press release - 29/05/2026 FCI Supports Teaching Concept for the Chemistry of Tomorrow The German Chemical Industry Fund (FCI) is supporting the course offering ‘DigiChemJN’ at the Faculty of Chemistry and Pharmacy. DigiChemJN strengthens students’ data literacy by providing them qualifications in data-based research methods, experimental datasets, and artificial intelligence (AI).https://www.gesundheitsindustrie-bw.de/en/article/press-release/fci-supports-teaching-concept-chemistry-tomorrow
Press release - 28/05/2026 An immune defence guide Which cellular processes ensure that immune responses are controlled precisely? A new study by the Institute of Cell Biology and Immunology Thurgau (BITG) and the University of Konstanz decodes a decisive signalling pathway.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immune-defence-guide
Press release - 27/05/2026 New Emmy Noether Junior Research group investigates the mode of action of Antimetabolite Chemotherapy How do antimetabolite cancer drugs damage the genetic material of malignantly transformed cells and thereby destroy them? How might these drugs be used more precisely, particularly in the treatment of pediatric tumors? A new research group led by Dr. Christopher Carnie, a scientist at the Heidelberg Faculty of Medicine at Heidelberg University, will address these questions. https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-emmy-noether-junior-research-group-investigates-mode-action-antimetabolite-chemotherapy
Press release - 26/05/2026 Heidelberg based development revolutionizes hepatitis D therapy worldwide: US Food and Drug Administration (FDA) approves hepatitis drug Hepcludex (bulevirtide) Joint press release of the Heidelberg Faculty of Medicine at Heidelberg University and the German Center for Infection Research: With the FDA approval of Hepcludex (bulevirtide), a therapy for chronic hepatitis D developed at the Heidelberg Faculty of Medicine at Heidelberg University, Heidelberg University Hospital, and the German Center for Infection Research (DZIF) has now reached the world’s most important pharmaceutical market.https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-based-development-revolutionizes-hepatitis-d-therapy-worldwide-us-food-and-drug-administration-fda-approves-hepatitis
Press release - 26/05/2026 How blood stem cells diversify Different types of bone marrow stem cells give rise to blood and immune cells. A team led by Simon Haas now reports in “Nature Cell Biology” how that diversity develops. The findings could help improve stem cell therapies, including treatments for blood cancers.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-blood-stem-cells-diversify
Press release - 21/05/2026 Breakthrough in synthetic cell research Living systems such as cells rely on membrane pores and channels to transport molecules, exchange signals, and organize biochemical reactions. These functions emerge from dynamic interactions between molecular components. Researchers at the University of Stuttgart have used DNA nanotechnology to develop a synthetic membrane architecture that mimics such interactions. https://www.gesundheitsindustrie-bw.de/en/article/press-release/breakthrough-synthetic-cell-research
Press release - 21/05/2026 Why pain persists long after injuries have healed Chronic pain is among the most common and burdensome health conditions worldwide. But which processes in the nervous system cause pain to be “learned” and thus persist long term? And how can insights into the mechanisms underlying chronic pain be translated into new therapeutic approaches? These questions have been at the core of Rohini Kuner’s research for many years.https://www.gesundheitsindustrie-bw.de/en/article/press-release/why-pain-persists-long-after-injuries-have-healed
Cancer prevention with a single jab - 20/05/2026 Therapeutic vaccine against HPV-induced tumours Persistent infections with human papillomaviruses (HPV) are the primary cause of cervical cancer. Researchers from Heidelberg have developed a promising therapeutic vaccine consisting of immunogenic virus peptides linked to silica nanoparticles, which is currently being investigated in preclinical studies. The vaccine activates specific cytotoxic T cells and is usable regardless of HLA type.https://www.gesundheitsindustrie-bw.de/en/article/news/therapeutic-vaccine-against-hpv-induced-tumours
Press release - 18/05/2026 Unlocking the Lung’s Ability to Heal: NK Cell Immunotherapy offers New Hope for Fibrosis Research jointly led by scientists at the Heidelberg site of the German Center for Lung Research and investigators in Boston at Massachusetts General Hospital and Harvard Medical School identifies a new immunotherapy-based approach for lung fibrosis: reactivating natural killer cell (NK cells) to eliminate senescent fibroblasts, reverse scarring and restore the lung’s ability to heal.https://www.gesundheitsindustrie-bw.de/en/article/press-release/unlocking-lungs-ability-heal-nk-cell-immunotherapy-offers-new-hope-fibrosis
Press release - 18/05/2026 Gene scissors show promise for treating a rare immune disorder Medical Center – University of Freiburg demonstrates a fundamental therapeutic approach for hereditary immune system defects in a mouse model. The safety profile of genome editing varies significantly depending on the method and cell type.https://www.gesundheitsindustrie-bw.de/en/article/press-release/gene-scissors-show-promise-treating-rare-immune-disorder
Press release - 11/05/2026 Alexander von Humboldt professorship for Simon Elsässer – “You can think of it as a kind of cellular memory” Prof. Dr Simon Elsässer will be awarded one of this year’s Alexander von Humboldt Professorships in Berlin on 12 May 2026. With funding of five million euros, Elsässer will strengthen Freiburg’s research focus ‘Signals of Life’ over the next five years. In this interview, he discusses complex decision-making processes in cells, the significance of signals and what makes the research environment in Freiburg so special.https://www.gesundheitsindustrie-bw.de/en/article/press-release/alexander-von-humboldt-professorship-simon-elsasser-you-can-think-it-kind-cellular-memory